A solute transport gene LvSLC5A8 of Litopenaeus vannamei and its encoded protein and application

By studying the solute transport gene LvSLC5A8 and its encoding protein in shrimp, the problem of WSSV infection control in shrimp farming was solved, and the recombinant protein of LvSLC5A8 was inhibited, which improved the antiviral ability of shrimp, reduced the risk of chemical drug contamination, and provided new A safe way to breed.

CN114875035BActive Publication Date: 2024-11-22MINJIANG UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210439388.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-25
Publication Date
2024-11-22
Estimated Expiration
2042-04-25

AI Technical Summary

Technical Problem

At this stage, there is a lack of effective means to control the white spot syndrome virus (WSSV) in shrimp farming. Traditional antibiotic use has led to increased bacterial resistance and environmental pollution, and the shrimp's immune system is insufficient to viral infection.

Method used

By studying the solute transport gene LvSLC5A8 and its encoding protein in vannabinoid shrimp, it was found that its expression was downregulated in WSSV infection. The LvSLC5A8 recombinant protein was prepared to inject shrimp into it to inhibit viral replication and improve the antiviral immunity of shrimp.

Benefits of technology

The LvSLC5A8 recombinant protein significantly reduces the replication level of WSSV in shrimps, provides new ideas for the development of anti-WSSV immunopreparations, reduces the risks brought by chemical drug contamination and antibiotics, and improves the safety of healthy breeding of shrimps.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114875035B_ABST
    Figure CN114875035B_ABST
Patent Text Reader

Abstract

The invention relates to the field of gene engineering technology, discloses a solute transport gene LvSLC5A8 of Litopenaeus vannamei and its encoded protein, and also discloses the application of the gene in inhibiting white spot syndrome virus (WSSV) infection; the nucleotide sequence of the LvSLC5A8 gene of Litopenaeus vannamei is the sequence shown in SEQ ID NO:1, and the amino acid sequence of the encoded protein is the sequence shown in SEQ ID NO:2, and experiments show that WSSV infection can inhibit the expression of the LvSLC5A8 gene; and after interfering with the WSSV very early gene WSV056, the transcriptional inhibition of the virus on LvSLC5A8 is significantly reduced; the LvSLC5A8 recombinant protein rLvSLC5A8 is prepared and injected into shrimp, which can reduce the replication level of WSSV virus in shrimp; and WSSV can inhibit the shrimp LvSLC5A8 to escape the host antiviral immune response. The recombinant protein rLvSLC5A8 can be used to enhance the immunity of shrimp, and has a great application prospect in the prevention and treatment of white spot syndrome virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of genetic engineering, and in particular to a solute transport gene SLC5A8 of Litopenaeus vannamei and its encoded protein and application thereof in resisting white spot syndrome virus (WSSV). Background Art

[0002] White Spot Syndrome Virus (WSSV) is a double-stranded DNA virus that seriously harms a variety of economic crustacean farming industries, mainly shrimp. It is one of the important monitoring targets of the National Aquatic Animal Disease Monitoring Program stipulated by the Ministry of Agriculture in 2017. There is currently no effective treatment. At present, the use of traditional drugs such as antibiotics is still the main means of controlling diseases. However, the long-term use of antibiotics not only causes the frequency of bacterial resistant strains to increase, but also causes the deterioration of the farming environment and coastal environmental pollution. Antibiotics and other drug residues not only harm national health, but also seriously affect the export of aquatic products. Therefore, in-depth understanding of the ways in which viruses invade hosts and the interaction of the host immune system, enhancing the antiviral ability of farmed animals, and developing safe and efficient disease prevention and control methods have become important breakthrough directions for the sustainable development of marine aquaculture.

[0003] In response to the above problems, the applicant used transgenic fruit fly lines in previous studies to analyze the fruit fly immune-related genes affected by WSSV very early genes and found that the transcription level of CG9657 gene was significantly downregulated in the fruit fly line overexpressing WSSV very early protein WSV056.

[0004] CG9657 is a member of the 5th subfamily (SLC5) of the solute carrier (SLC) superfamily. The solute carrier (SLC) superfamily encodes a group of membrane transport proteins on the cell membrane, mediating the transmembrane transport of various solutes between the cell and the external environment or inside the cell, and participating in important functions such as nutrition and metabolism of body activities, neurotransmitter transport and signal transduction. In addition, the substrates transported by this superfamily also involve the cardiovascular system, immune system and other aspects. SLC superfamily members are widely present in prokaryotes and eukaryotes, with more than 400 in humans, and a quarter of them are directly related to human diseases. SLC5 subfamily members encode a group of Na + / Glucose co-transporter, a sodium-coupled carrier for transporting short-chain fatty acids, glucose, lactate, propionate, butyrate, pyruvate, niacin and iodide. Human SLC5 subfamily members are responsible for the absorption of glucose in the small intestine and primary urine, and their functional defects lead to poor absorption of glucose and galactose.

[0005] There is a homologous gene of CG9657 in shrimp. This gene has the highest similarity with the 8th member of the 5th subfamily of the human SLC superfamily (SLC5A8), so it is named LvSLC5A8. The protein encoded by the human SLC5A8 gene is also called sodium-coupled monocarboxylate transporter (SMCT1). The expression of this gene is downregulated or absent in various tumor tissues, and methylation of its promoter region can lead to the occurrence of various tumors. At present, most of the research on the function of SLC5A8 focuses on the mechanism of inhibiting tumor growth, and there are no relevant reports on its antiviral function.

[0006] The present invention found that the transcription level of the LvSLC5A8 gene of Penaeus vannamei was significantly downregulated during the WSSV infection process, and interfering with the expression of WSV056 in the shrimp can reduce the inhibition level of the WSSV virus on LvSLC5A8, suggesting that the expression of the LvSLC5A8 gene of the shrimp may be regulated by the viral gene WSV056. After preparing the LvSLC5A8 recombinant protein and injecting it into the shrimp, an infection experiment was conducted, and it was found that the overexpression of LvSLC5A8 significantly reduced the number of WSSV copies in the infected shrimp, indicating that LvSLC5A8 has antiviral immune function. The downregulation of LvSLC5A8 during WSSV infection may be a mechanism for the virus to evolve to inhibit the antiviral function of the LvSLC5A8 expression protein.

[0007] In summary, LvSLC5A8 of Penaeus vannamei can improve the antiviral immunity of Penaeus vannamei, and its recombinant protein can be used to prepare anti-WSSV immune preparations, which also has broad application prospects in production practice. There is currently a lack of effective WSSV control drugs, and the inventors found through experiments that the LvSLC5A8 gene of Penaeus vannamei and its encoded protein can inhibit the infection of WSSV, providing a new idea for the development of WSSV prevention and control. Summary of the invention

[0008] To solve the above technical problems, the present invention provides a solute transport gene LvSLC5A8 of Penaeus vannamei, the nucleotide sequence of the solute transport gene LvSLC5A8 of Penaeus vannamei is the sequence shown in SEQ ID NO:1, and the amino acid sequence of the encoded protein is the sequence shown in SEQ ID NO:2.

[0009] In order to solve the above technical problems, the present invention also provides the use of the solute transport gene LvSLC5A8 of Litopenaeus vannamei and its encoded protein in inhibiting WSSV infection.

[0010] Compared with the prior art, the invention has the following beneficial effects: the invention finds that the LvSLC5A8 gene of Penaeus vannamei can improve the antiviral immunity of Penaeus vannamei, and experiments show that the replication level of WSSV in the shrimp can be inhibited by injecting the recombinant protein rLvSLC5A8, and can be used to prepare anti-WSSV immune preparations. The research results of the invention provide a beneficial protection approach for the prevention and treatment of white spot syndrome virus in shrimp, and its use can reduce or eliminate the use of conventional antibiotics and disinfectants, reduce the pollution caused by chemical drugs and the drug resistance safety risks caused by antibiotics, and has great application prospects in the healthy breeding of shrimp. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 It is a sequence alignment diagram of the present invention's Litopenaeus vannamei LvSLC5A8 and the closest predicted protein PjSMCT-1;

[0012] Figure 2 This is the regulatory effect of WSV056 on LvSLC5A8 during the infection of shrimp with WSSV virus. ** indicates p<0.01;

[0013] Figure 3 Purification of the recombinant fusion protein of Penaeus vannamei LvSLC5A8-His of the present invention;

[0014] Figure 4 The LvSLC5A8-His protein of the present invention inhibits the replication of WSSV virus in Litopenaeus vannamei. ** indicates p<0.01. DETAILED DESCRIPTION

[0015] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the implementation rules and drawings. The exemplary implementation modes of the present invention and their descriptions are only used to explain the present invention and are not intended to limit the present invention.

[0016] As shown in Table 1, all primers were synthesized by Shanghai Bioengineering Co., Ltd. Unless otherwise specified, the concentration of all primers was 10 mM.

[0017] Table 1 Primer sequences used in Examples 1-4

[0018]

[0019]

[0020] Example 1. Cloning and sequencing of the solute transport gene LvSLC5A8 of Litopenaeus vannamei

[0021] Materials preparation: Escherichia coli DH5α competent cells (Shanghai Bioengineering Co., Ltd.), Escherichia coli BL21 (DE3) competent cells (Beijing Tiangen Biochemical), pMD18-T vector (TaKaRa, China), prokaryotic expression vector pET30A (Solaibao, China), genome extraction kit (TaKaRa, China), PrimeScript RT Reagent Kit with gDNAEraser (TaKaRa, China), SYBR Premix Ex Taq TM II (TaKaRa, China), T7 Ribo-MAX TM ExpressRNAi System kit (Promega, USA), Ni-NTA purification medium (GenScript, China).

[0022] 1. Extraction of total RNA: About 0.5 g of intestinal tissue of Penaeus vannamei was rinsed with sterile saline and immediately placed in a liquid nitrogen pre-cooled mortar, quickly ground into powder in liquid nitrogen, added with 1 mL of Trizol extraction solution, and total RNA was extracted according to the Invitrogen instructions. The quality of RNA was tested by UV spectrophotometer.

[0023] 2. RACE amplification and clone identification:

[0024] According to the sequence fragment of LvSLC5A8 gene in the laboratory transcriptome database, two upstream primers and two downstream primers were designed (see Table 1), and TaKaRa's 3′-Full RACE Core Set and 5′-Full RACE kit were used for 3′ and 5′ end amplification, respectively. The PCR product was purified according to the kit instructions, and the 3′ and 5′ end fragments of the LvSLC5A8 gene were TA cloned using the pMD18-T vector, and then transformed into Escherichia coli DH5α competent cells and coated on LB plates with ampicillin (Amp) resistance. White colonies were picked and sent for sequencing (Shanghai Bioengineering Co., Ltd.). After splicing the sequencing results, the full-length cDNA was obtained. Analysis showed that the sequence contained an open reading frame (ORF) with a full length of 2115 bp, and the nucleotide sequence was shown in SEQ ID NO.1; the protein encoded by the ORF had 704 amino acids, and its sequence was shown in SEQ ID NO.2.

[0025] The protein encoded by the LvSLC5A8 gene of Penaeus vannamei was compared with the NCBI database using BlastP (http: / / www.ncbi.nim.nih.gov / ), and it was found that the protein encoded by the gene PjSMCT-1 predicted based on the Japanese shrimp genome had the highest similarity with the protein, with a sequence identity of 77.66%. Figure 1As shown, the sequence of LvSLC5A8 of Litopenaeus vannamei is not consistent with any previously published protein sequence, indicating that it is a newly discovered protein and its encoding gene LvSLC5A8 is also a newly discovered gene. CD Search (https: / / ncbi.nlm.nih.gov / Structure / cdd / wrpsb.cgi) was used to search for the conserved domain of the target protein, and it was found that the protein encoded by the LvSLC5A8 gene has the conserved domain of the SLC5 gene subfamily, indicating that LvSLC5A8 has the structural characteristics of a solute transporter.

[0026] Example 2. Regulatory effect of WSV056 on LvSLC5A8 during shrimp infection

[0027] With T7 Ribo-MAX TM The double-stranded RNA (dsRNA) of WSV056 and control enhanced green fluorescent protein (EGFP) genes was prepared by using the Express RNAi System kit. The primer sequences used are shown in Table 1. The third abdominal segment of the shrimp Penaeus vannamei was injected intramuscularly at a dose of 20 μg / g. 48 hours after the first injection, the uninfected group was injected with an equal amount of dsRNA, and the infected group was injected with an equal amount of dsRNA and 5×10 6 WSSV virus mixture, with the saline injection group as a blank control. 24 hours after the second injection, 9 shrimps were randomly selected from the injection group, and the intestinal tissue was isolated. The intestinal tract of each three shrimps was mixed together as a sample, with a total of three parallel samples. Intestinal tissue RNA was extracted as described in Example 1 and the total RNA was reversed to cDNA using PrimeScript RT Reagent Kit, and SYBR Premix Ex Taq TM II kit was used to detect the transcription level of LvSLC5A8 using fluorescence quantitative PCR (qRT-PCR). Figure 2 As shown, the transcription level of LvSLC5A8 decreased by 38% 24 hours after WSSV infection, and interfering with the expression of WSSV viral gene WSV056 could greatly weaken the inhibition of WSSV infection on LvSLC5A8, indicating that WSSV virus can inhibit the expression of host LvSLC5A through WSV056.

[0028] Example 3. Expression of recombinant protein of Litopenaeus vannamei LvSLC5A8 gene

[0029] 1. Construction of prokaryotic recombinant expression vector pET30A-LvSLC5A8

[0030] Using cDNA as a template, PCR was used to amplify the LvSLC5A8 open reading frame (primers are shown in Table 1). After the PCR product was purified, the open reading frame of the LvSLC5A8 gene was cloned by TA using the pMD18-T vector. Then it was transformed into Escherichia coli DH5α competent cells and coated on LB plates with Amp resistance. White colonies were picked as templates, and the PCR products were purified after amplification using recombinant expression primers (Table 1).

[0031] The pET30A vector and the purified LvSLC5A8 PCR product were double-digested with KpnI and HindIII, detected by electrophoresis, purified by gel recovery, ligated and transformed into E. coli DH5α, and coated on LB plates with Amp resistance. White colonies were selected for PCR identification, and positive clones were sent to Shanghai Bioengineering Co., Ltd. for sequencing verification.

[0032] 2. Inducible expression of rLvSLC5A8 fusion protein

[0033] The recombinant plasmid pET30A-LvSLC5A8 with correct sequencing was transformed into competent E. coli BL21 (DE3), and the pET30A empty plasmid was transformed as a control. Single clone colonies were picked and cultured in LB liquid medium containing 100μg / mL Amp at 37℃ until OD 600 was 0.6, and isopropyl-β-D-thiogalactopyranoside (IPTG) with a final concentration of 1mmol / L was added to induce expression at 16℃ overnight, and the bacteria were collected; the bacteria were resuspended in PBS, ultrasonically disrupted at 4℃ for 6min, and the bacterial solution after ultrasonic disruption was centrifuged at 4℃ at 10000r / min for 20min, and the supernatant and precipitate were separated. The recombinant protein rLvSLC5A8 was purified using Ni-NTA purification medium, and the electrophoresis results showed a clear band at around 82kDa ( Figure 3 ), removing the approximately 5 kDa His-Tag fusion protein added by the vector, which is consistent with the predicted result that the vannamei shrimp LvSLC5A8 is 77 kDa.

[0034] Example 4. Antiviral function of rLvSLC5A8 recombinant protein of Penaeus vannamei in living Penaeus vannamei

[0035] The anti-WSSV activity of rLvSLC5A8 recombinant protein was analyzed in vivo using Litopenaeus vannamei. The shrimp were randomly divided into three groups, with 25 in each group. The two experimental groups were injected with 50 μL containing 10 μg rLvSLC5A8 protein or His-Tag protein and 5×10 6 The third group was the control group, which was injected with 50 μL PBS buffer and 5×10 6Mixture of WSSV virus copies. At 24 hours and 48 hours after injection, 9 shrimps were randomly selected from each group, muscle tissue was separated, and the muscles of three shrimps were mixed together as a sample, with a total of three parallel samples. The genomic DNA of muscle tissue was extracted using a genome extraction kit, and the pMD-18-T plasmid containing WSSV fragments was used as an internal reference (primers are shown in Table 1). The extracted DNA template was compared with the internal reference plasmid to obtain the WSSV copy number in muscle tissue. The results are shown in Figure 4 As shown, the number of WSSV virus copies in shrimp injected with recombinant protein rLvSLC5A8 was significantly lower than that in the control group 24 and 48 hours after virus infection, indicating that rLvSLC5A8 has an inhibitory effect on the replication of WSSV in the host.

[0036] The above is an embodiment of the present invention. The above embodiments and the specific parameters in the embodiments are only for the purpose of clearly describing the invention verification process, and are not intended to limit the patent protection scope of the present invention. The patent protection scope of the present invention is still subject to its claims. Any equivalent structural changes made by using the contents of the description and drawings of the present invention should be included in the protection scope of the present invention. Sequence Listing <110> Minjiang College <120> A solute transport gene LvSLC5A8 of Litopenaeus vannamei and its encoded protein and application <130> 2022 <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 2115 <212> DNA <213> Litopenaeus vannamei <400> 1 <210> 2 <211> 704 <212> PRT <213> Litopenaeus vannamei <400> 2 Met Ser Leu Asn Thr Gln Glu Leu Val Asp Arg Phe Thr Trp Val Asp 1 5 10 15 Tyr Thr Val Phe Gly Leu Met Leu Ala Val Ser Ala Ala Ile Gly Ile 20 25 30 Phe Tyr Gly Leu Cys Ser Arg Lys Lys Gln Asp Thr Lys Glu Phe Leu 35 40 45 Met Ala Gly Lys Ser Met Thr Thr Phe Pro Val Ala Met Ser Leu Ile 50 55 60 Ala Ser Phe Met Ser Ala Ile Thr Leu Leu Gly Thr Pro Ala Glu Val 65 70 75 80 Tyr Gln Phe Gly Phe Leu Tyr Trp Leu Ile Gly Trp Ser Tyr Ile Leu 85 90 95 Val Met Pro Ser Ala Ala Tyr Leu Tyr Phe Pro Val Phe His Lys Leu 100 105 110 Gln Val Thr Ser Ala Tyr Glu Tyr Leu Glu Ile Arg Phe Asn Arg Lys 115 120 125 Ile Arg Trp Met Gly Ser Phe Thr Phe Ile Ile Gln Met Cys Leu Tyr 130 135 140 Met Wing Ile Val Val Tyr Wing Pro Wing Leu Wing Leu Ser Gln Val Thr 145 150 155 160 Gly Met Asn Val Tyr Phe Ser Val Ser Leu Ile Ser Phe Val Cys Ile 165 170 175 Phe Tyr Thr Thr Leu Gly Gly Met Lys Ala Val Leu Trp Thr Asp Ala 180 185 190 Ile Gln Val Ile Ile Met Phe Gly Ser Val Leu Phe Val Ile Ile Lys 195 200 205 Gly Thr Ile Asp Met Gly Gly Phe Glu Tyr Val Trp Ala Lys Asn Lys 210 215 220 Glu Trp Asp Arg Ile Glu Leu Val Asn Phe Asp Pro Asn Pro Thr Thr 225 230 235 240 Arg His Ser Ile Trp Ser Leu Ile Ile Gly Gly Tyr Phe Thr Trp Ile 245 250 255 Ala Asn Tyr Gly Val Asn Gln Ala Gln Val Gln Arg Tyr Leu Cys Val 260 265 270 Arg Thr Lys Ala Met Val Glu Arg Ala Leu Trp Ile Asn Met Ala Gly 275 280 285 Leu Phe Val Leu Met Ile Ser Cys Ala Phe Gly Gly Leu Val Ile Phe 290 295 300 Ala Arg Tyr Trp Asp Cys Asp Pro Ile Ser Ala Gly Val Val Ser Ser 305 310 315 320 Ala Asp Gln Leu Met Pro Leu Phe Val Met Asp Ile Leu Gly Gly Trp 325 330 335 Arg Gly Leu Pro Gly Leu Phe Val Ala Gly Ile Phe Ala Gly Ala Leu 340 345 350 Ser Thr Val Ser Ser Gly Met Asn Ser Leu Ala Ala Ile Val Leu Glu 355 360 365 Asp Phe Leu Lys Asn Gly Cys Tyr Lys Thr Ile Ser Glu Arg Ala Ser 370 375 380 Thr Val Ala Ser Lys Leu Leu Ser Leu Leu Phe Gly Leu Leu Thr Phe 385 390 395 400 Ala Leu Val Phe Val Ala Glu Gln Leu Gly Gly Val Leu Ser Ala Ala 405 410 415 Leu Ser Ile Phe Gly Met Val Gly Gly Pro Leu Leu Gly Leu Phe Ser 420 425 430 Leu Gly Met Phe Phe Pro Trp Ala Asn Ser Val Gly Ala Ala Val Gly 435 440 445 His Val Cys Gly Leu Ala Phe Met Phe Trp Ile Gly Val Gly Thr Gln 450 455 460 Val Gly Leu Ala Thr Gly Asp Val Thr Tyr Pro Lys Lys Pro Leu Ser 465 470 475 480 Val Ser Gly Cys Asn Phe Thr Glu Thr Thr Ala Gly Phe Ser Ser Thr 485 490 495 Glu Ala Ala Phe Leu Thr Ser Ser Glu Thr Ser Phe Val Pro Thr Glu 500 505 510 Pro Pro Ser Gly Ile Leu Gly Leu Tyr Asn Leu Ser Tyr Met Trp Tyr 515 520 525 Ser Ala Thr Gly Cys Phe Thr Val Ile Val Val Gly Leu Val Val Ser 530 535 540 Leu Leu Thr Gly Gly Arg Asp Leu Gly Ser Leu Asp Pro Arg Thr Leu 545 550 555 560 Ser Pro Pro Leu Leu Trp Leu Arg Lys Trp Val Pro Ala Leu Arg Ala 565 570 575 Val Gly Glu Asn Leu Asn Asp Glu Leu Asp Glu Leu Arg Glu Thr Ser 580 585 590 Thr Ser Glu Lys Asp Gly Gly Asp Leu Thr Ser Gly Asp Leu Thr Ser 595 600 605 Ile Ile Ser Lys Leu Pro Pro Arg Thr Leu Asp Gly Ser Leu Lys Glu 610 615 620 Ala Lys Thr Asp Lys Leu Pro Val Val Leu Asp Ala Pro Ala Leu Pro 625 630 635 640 Arg Glu Asp Pro Ala Lys Leu Lys Ser Ser Met Ser Asp Ser Ala Phe 645 650 655 Glu Asp Gly Ser Ser Ser Leu Gly Ile Leu Glu Glu Glu Lys Glu Glu 660 665 670 Asp Gly Arg Ser Glu Asp Leu Gly Leu Glu Asn Ser Ala Met Ser Val 675 680 685 Asp Asp Glu Asp Gly Ser Thr Ser Leu Thr Ile Pro Thr Thr His Leu 690 695 700

Claims

1. A protein encoding a solute transport gene LvSLC5A8 of Litopenaeus vannamei, characterized in that: The amino acid sequence of the encoded protein is the sequence shown in SEQ ID NO:

2.

2. Use of the encoded protein of the solute transport gene LvSLC5A8 of Penaeus vannamei according to claim 1 in the preparation of an immune preparation for inhibiting WSSV infection in Penaeus vannamei.